Johnson & Johnson acquires biotech firm Proteologix for $850m, focusing on bispecific antibodies for immune-mediated diseases like eczema and asthma.

Johnson & Johnson is acquiring Proteologix, a privately held biotech company, for $850 million in cash. Proteologix is focused on bispecific antibodies for immune-mediated diseases, with experimental treatments for atopic dermatitis (eczema) and asthma. The acquisition includes PX128, a bispecific antibody in phase 1 development for eczema and asthma, and PX130, in preclinical development for eczema.